Cybin (HELP) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- —
- Estimate
- -$1.38
- Surprise
- —
- Score today
- 4.7/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
Coverage in the report window
- Airsculpt Technologies, Barrick Mining And Other Big Stocks Moving Lower In Monday’s Pre-Market Session — benzinga, 2026-08-10
Where TrendMatrix's rating stands now
TrendMatrix currently rates HELP Sell at 4.7/10; no pre/post engine snapshot brackets this report.
0 of the last 4 quarters beat the estimate. Next scheduled report: 2026-11-12.
What argues against it
- DATA_ISSUE: analyst_target_implausible (raw $41.09 vs price $8.84 — ratio 4.6×). Rejected, falling back to technical TP.
- Quality below floor (1.2 < 4.0)
- EARNINGS_PROXIMITY:2d<=7d
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $8.84
- Price target
- $11.51
- Stop
- $8.22
- Upside to target
- +30.2%
Model outputs from TrendMatrix’s engine as of 2026-11-10 — shown for context, not personalized investment advice.
HELP at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $684.7M
- P/E (fwd)
- -5.3
- 52-week range
- $3.76–$15.15
- Off 52-week high
- 41.7%
- RSI (14)
- 33
- Volume vs avg
- 0.19×
- Score today
- 4.7/10